Over the past 30 years, 18,000 clinical trials that have been registered in Australia, with the sector contributing $1.4 billion to Australia’s economy annually. Trials are a critical aspect of evidence-based medicine, and are essential for testing how new treatments, tests and vaccines will work. In New Zealand they contribute $146 million to the New Zealand economy.
Australia and New Zealand have established themselves as ideal locations to host clinical trials due to their diverse participant populations, sophisticated healthcare and research environments as well as government backed support. Both countries have adopted the International Council for Harmonisation (ICH) Guideline for Good Clinical Practice (GCP) to ensure all trials collect high quality and credible data that is internationally recognised.
To capitalise on this unique position and growth, a coordinated multi-site clinical research operation was missing.
Now, three of the largest clinical trial organisations across Australia and New Zealand have united to form Momentum Clinical Research – an end-to-end clinical research network with sites that have been operating for over 20 years. Combined, they have 13 site locations across the Trans-Tasman and are set to open more locations to allow more studies to take place and enable everyday people to access new and emerging therapies.
In February 2024, New Zealand’s renowned P3 Research joined forces with Australia’s AusTrials and Holdsworth House to form Momentum Clinical Research. The combined entity can now provide sponsors a single point of contact for their current 13 sites across the two countries,
Momentum Clinical Research aims to provide quick responses to feasibility requests, faster study starts and accelerated recruitment – all leading to the delivery of high-quality results for Phase 1b-IV clinical trials. Momentum Clinical Research has become the only Trans-Tasman network of clinical trial sites.
Australian Health Journal spoke with Aus Trials Research Director, Dr Munro Neville, on the Australian clinical trial landscape more broadly and reasons for creating a Trans-Tasman clinical research organisation.
Further growth in the industry is expected, with the Australian Government having pledged $750 million to increase clinical trial activity between 2022-2032. Similarly, the New Zealand Government has invested $98 million into health research funding from 2017-2027 to facilitate the conduct of clinical trials.
-
Detection and prevention of Alzheimer’s Disease and Related Dementias
Professor Vicky Vass serves as the Chief Executive Officer of Alzheimer’s Research Australia, which is based in Perth, Western Australia. Australian Health Journal met with Professor Vass to hear of the organisation’s mission to solve the mysteries surrounding Alzheimer’s disease, and focus on detection as the key to their efforts.
-
Interventional radiologists offer alternative to hysterectomy
In Australia in the last five years, an estimated 6066 women per year have undergone hysterectomies to treat fibroid-related diseases, while just 145 women each year have undergone a uterine artery embolisation, or UAE.
The procedure can effectively treat the majority of bleeding uterine fibroids. Each year, thousands of Australian women undergo invasive and life-altering hysterectomies to treat debilitating pain and blood loss caused by uterine fibroids. But there’s another option: a minimally invasive, pin-hole procedure that treats the symptoms, yet leaves the uterus intact.
-
WA and QLD RSV Immunisation programs show drops in infant hospitalisations
RSV is the number one cause of hospitalisation of Australian children under five years of age, according to the Immunisation Foundation of Australia (IFA). There are mounting concerns that Australians at greatest risk of severe Respiratory Syncytial Virus, or RSV will miss out on protection against the lung infection, with the Federal Government failing to commit to a national RSV immunisation program.
